App aims to boost breast cancer drug adherence

NCT ID NCT06905301

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 20, 2026 · Updated 13 times

Summary

This study looks at whether a mobile app can help people with hormone-receptor-positive, HER2-negative stage II or III breast cancer stick to their prescribed treatment of ribociclib plus an aromatase inhibitor. About 240 participants will either use the app or not, and researchers will compare how many in each group continue their therapy for 12 months. The app provides information on relapse risks and managing side effects to support adherence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Pskov, Russia, 180000, Russia
Novartis Investigative Site
RECRUITING

Moscow, 115304, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194017, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194291, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 197758, Russia
Novartis Investigative Site
RECRUITING

Sestroretsk, 197706, Russia
Novartis Investigative Site
RECRUITING

Ufa, 450054, Russia

Conditions

Explore the condition pages connected to this study.

BREAST CANCER